S&P 500   3,615.81 (-0.62%)
DOW   29,602.27 (-1.03%)
QQQ   297.68 (-0.44%)
AAPL   118.90 (+1.98%)
MSFT   212.38 (-1.32%)
FB   274.25 (-1.28%)
GOOGL   1,752.62 (-1.92%)
AMZN   3,140.80 (-1.71%)
TSLA   577.54 (-1.40%)
NVDA   528.28 (-0.41%)
BABA   265.39 (-4.01%)
CGC   28.76 (-0.83%)
GE   10.30 (-0.96%)
MU   64.72 (+0.76%)
AMD   91.93 (+5.44%)
T   28.90 (-0.45%)
NIO   51.28 (-5.04%)
F   9.09 (+0.00%)
ACB   11.27 (+7.64%)
NFLX   485.90 (-1.11%)
BA   213.24 (-1.51%)
GILD   60.17 (+0.23%)
DIS   147.56 (+0.29%)
S&P 500   3,615.81 (-0.62%)
DOW   29,602.27 (-1.03%)
QQQ   297.68 (-0.44%)
AAPL   118.90 (+1.98%)
MSFT   212.38 (-1.32%)
FB   274.25 (-1.28%)
GOOGL   1,752.62 (-1.92%)
AMZN   3,140.80 (-1.71%)
TSLA   577.54 (-1.40%)
NVDA   528.28 (-0.41%)
BABA   265.39 (-4.01%)
CGC   28.76 (-0.83%)
GE   10.30 (-0.96%)
MU   64.72 (+0.76%)
AMD   91.93 (+5.44%)
T   28.90 (-0.45%)
NIO   51.28 (-5.04%)
F   9.09 (+0.00%)
ACB   11.27 (+7.64%)
NFLX   485.90 (-1.11%)
BA   213.24 (-1.51%)
GILD   60.17 (+0.23%)
DIS   147.56 (+0.29%)
S&P 500   3,615.81 (-0.62%)
DOW   29,602.27 (-1.03%)
QQQ   297.68 (-0.44%)
AAPL   118.90 (+1.98%)
MSFT   212.38 (-1.32%)
FB   274.25 (-1.28%)
GOOGL   1,752.62 (-1.92%)
AMZN   3,140.80 (-1.71%)
TSLA   577.54 (-1.40%)
NVDA   528.28 (-0.41%)
BABA   265.39 (-4.01%)
CGC   28.76 (-0.83%)
GE   10.30 (-0.96%)
MU   64.72 (+0.76%)
AMD   91.93 (+5.44%)
T   28.90 (-0.45%)
NIO   51.28 (-5.04%)
F   9.09 (+0.00%)
ACB   11.27 (+7.64%)
NFLX   485.90 (-1.11%)
BA   213.24 (-1.51%)
GILD   60.17 (+0.23%)
DIS   147.56 (+0.29%)
S&P 500   3,615.81 (-0.62%)
DOW   29,602.27 (-1.03%)
QQQ   297.68 (-0.44%)
AAPL   118.90 (+1.98%)
MSFT   212.38 (-1.32%)
FB   274.25 (-1.28%)
GOOGL   1,752.62 (-1.92%)
AMZN   3,140.80 (-1.71%)
TSLA   577.54 (-1.40%)
NVDA   528.28 (-0.41%)
BABA   265.39 (-4.01%)
CGC   28.76 (-0.83%)
GE   10.30 (-0.96%)
MU   64.72 (+0.76%)
AMD   91.93 (+5.44%)
T   28.90 (-0.45%)
NIO   51.28 (-5.04%)
F   9.09 (+0.00%)
ACB   11.27 (+7.64%)
NFLX   485.90 (-1.11%)
BA   213.24 (-1.51%)
GILD   60.17 (+0.23%)
DIS   147.56 (+0.29%)
Log in
NASDAQ:ZEAL

Zealand Pharma A/S Stock Forecast, Price & News

$37.63
+1.33 (+3.66 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$37.63
Now: $37.63
$37.63
50-Day Range
$32.10
MA: $37.75
$42.68
52-Week Range
$22.00
Now: $37.63
$44.60
Volume4,000 shs
Average Volume6,781 shs
Market Capitalization$1.50 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.19
Zealand Pharma A/S, a biotechnology company, engages in the discovery and development of peptide-based medicines in Denmark. It has a portfolio of medicines in development stage focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes glepaglutide, a long acting GLP-2 analog, which is in Phase 3 clinical trials for the treatment of short bowel syndrome; and dasiglucagon, a stable glucagon analog for the treatment of severe hypoglycemia in diabetes and congenital hyperinsulinism, as well as for use in dual-hormone artificial pancreas for automated diabetes management. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; and Beta Bionics, Inc. to initiate home-use trial of the iLet bionic pancreas with dasiglucagon for autonomous bihormonal treatment of type 1 diabetes, as well as research agreement with Orbit Discovery Ltd. and Torrey Pines Institute for Molecular Studies. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.
Read More
Zealand Pharma A/S logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.00 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZEAL
CUSIPN/A
Phone45-8877-3600
Employees313

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.20 million
Book Value$5.85 per share

Profitability

Net Income$-85,670,000.00
Net Margins-214.31%

Miscellaneous

Market Cap$1.50 billion
Next Earnings Date3/11/2021 (Estimated)
OptionableNot Optionable
$37.63
+1.33 (+3.66 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZEAL News and Ratings via Email

Sign-up to receive the latest news and ratings for ZEAL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zealand Pharma A/S (NASDAQ:ZEAL) Frequently Asked Questions

How has Zealand Pharma A/S's stock price been impacted by Coronavirus (COVID-19)?

Zealand Pharma A/S's stock was trading at $28.10 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ZEAL stock has increased by 33.9% and is now trading at $37.63.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Zealand Pharma A/S?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zealand Pharma A/S in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Zealand Pharma A/S
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Zealand Pharma A/S?

Wall Street analysts have given Zealand Pharma A/S a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Zealand Pharma A/S wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Zealand Pharma A/S's next earnings date?

Zealand Pharma A/S is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Zealand Pharma A/S
.

How were Zealand Pharma A/S's earnings last quarter?

Zealand Pharma A/S (NASDAQ:ZEAL) issued its quarterly earnings results on Tuesday, November, 17th. The company reported ($5.76) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($5.58) by $0.18. The business had revenue of $8.88 million for the quarter, compared to analyst estimates of $16.41 million. Zealand Pharma A/S had a negative net margin of 214.31% and a negative return on equity of 38.34%.
View Zealand Pharma A/S's earnings history
.

What price target have analysts set for ZEAL?

2 brokerages have issued twelve-month target prices for Zealand Pharma A/S's stock. Their forecasts range from $42.00 to $44.00. On average, they anticipate Zealand Pharma A/S's share price to reach $43.00 in the next year. This suggests a possible upside of 14.3% from the stock's current price.
View analysts' price targets for Zealand Pharma A/S
.

Who are some of Zealand Pharma A/S's key competitors?

What other stocks do shareholders of Zealand Pharma A/S own?

Who are Zealand Pharma A/S's key executives?

Zealand Pharma A/S's management team includes the following people:
  • Dr. Emmanuel Dulac Pharm.D., PharmD, Ph.D., MBA, CEO & Pres (Age 51)
  • Mr. Matthew Donald Dallas, Sr. VP & CFO (Age 45)
  • Ms. Hanne Heidenheim Bak, Sr. Project Director, R&D Operations Mang. and Employee Representative Director (Age 67)
  • Mr. Adam Sinding Steensberg M.D., Exec. VP of R&D and Chief Medical Officer (Age 46)
  • Mr. Ivan Mourits Møller, Sr. VP of Technical Devel. & Operations (Age 48)
  • Rie Schultz Hansen, Interim Chief Scientific Officer & VP of Research
  • Lani Pollworth Morvan, Investor Relations & Communications Officer
  • Mr. Mads Kronborg, Head of Investor Relations & Communication
  • Søren Vitfell Keller, Head of Legal Affairs
  • Mr. Marino Garcia M.B.A., Sr. VP of Corp. & Bus. Devel. (Age 54)

When did Zealand Pharma A/S IPO?

(ZEAL) raised $75 million in an IPO on Wednesday, August 9th 2017. The company issued 3,900,000 shares at a price of $19.30 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

What is Zealand Pharma A/S's stock symbol?

Zealand Pharma A/S trades on the NASDAQ under the ticker symbol "ZEAL."

Who are Zealand Pharma A/S's major shareholders?

Zealand Pharma A/S's stock is owned by many different institutional and retail investors. Top institutional investors include Jane Street Group LLC (0.07%), Morgan Stanley (0.02%) and JPMorgan Chase & Co. (0.00%).

Which major investors are selling Zealand Pharma A/S stock?

ZEAL stock was sold by a variety of institutional investors in the last quarter, including Jane Street Group LLC.

Which major investors are buying Zealand Pharma A/S stock?

ZEAL stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., and Morgan Stanley.

How do I buy shares of Zealand Pharma A/S?

Shares of ZEAL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zealand Pharma A/S's stock price today?

One share of ZEAL stock can currently be purchased for approximately $37.63.

How big of a company is Zealand Pharma A/S?

Zealand Pharma A/S has a market capitalization of $1.50 billion and generates $6.20 million in revenue each year. The company earns $-85,670,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis. Zealand Pharma A/S employs 313 workers across the globe.

What is Zealand Pharma A/S's official website?

The official website for Zealand Pharma A/S is www.zealandpharma.com.

How can I contact Zealand Pharma A/S?

Zealand Pharma A/S's mailing address is SYDMARKEN 11, COPENHAGEN G7, 2860. The company can be reached via phone at 45-8877-3600 or via email at [email protected]

This page was last updated on 11/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.